RCUS•benzinga•
Barclays Maintains Overweight on Arcus Biosciences, Lowers Price Target to $14
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 23, 2025 by benzinga